Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Dont walk into this place if youre looking for a clinician to actually listen to you. Clark G
KLOwen is custom done right
Shorter faster treatment option
See: Statistics from Altmetric.com Introduction Major neurocognitive disorders such as Alzheimers disease (AD), vascular dementia (VaD) and Parkinsons disease/Lewy body dementia (PD/LBD) are a major global health challenge.1 It is estimated that over 55 million people live with dementia globally, a number projected to reach more than 150 million by 2050.2 These diseases significantly impact patients and carers quality of life, while also placing a considerable burden on healthcare systems.3 Despite ongoing advances in understanding their physiopathology, effective treatmentsespecially disease-modifying onesremain limited.4 In this context, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being proposed as potential drugs for managing cognitive disorders owing to their putative ability to affect neurobiological and metabolic pathways implicated in neurodegeneration.5 GLP-1RAs are a class of medications currently including exenatide, lixisenatide, dulaglutide, liraglutide, semaglutide and tirzepatide (a dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist), initially developed for type 2 diabetes mellitus (T2DM).6 They mimic the action of endogenous GLP-1, which is secreted in response to nutrient intake and plays a key role in glucose homeostasishence the name incretin mimetics
2008;3:e3163
The FDA approved once-daily oral semaglutide (Wegovy) at 25 mg on 22 December 2025, making it the first oral GLP-1 approved specifically for chronic weight management in the US
